Evidence map›Paper›PMID 38730695›Full record

ArticleCancers2024

Long-Term Results of Stereotactic Radiotherapy in Patients with at Least 10 Brain Metastases at Diagnosis.

Rémy Kinj, Andreas Felix Hottinger, Till Tobias Böhlen, Mahmut Ozsahin, Véronique Vallet, Vincent Dunet, Hasna Bouchaab, Solange Peters, Constantin Tuleasca, Jean Bourhis and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancers, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Review
  3. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Rémy KinjDepartment of Radiation Oncology, Lausanne University Hospital and University of Lausanne, CHUV, Rue du Bugnon 46, CH-1011 Lausanne, Switzerland.ORCID 0000-0001-9283-7227
Andreas Felix HottingerLundin Family Brain Tumor Centre, Departments of Oncology & Clinical Neurosciences, Hospital and University of Lausanne, CH-1011 Lausanne, Switzerland.
Till Tobias BöhlenLundin Family Brain Tumor Centre, Departments of Oncology & Clinical Neurosciences, Hospital and University of Lausanne, CH-1011 Lausanne, Switzerland.ORCID 0000-0001-7408-0187
Mahmut OzsahinDepartment of Radiation Oncology, Lausanne University Hospital and University of Lausanne, CHUV, Rue du Bugnon 46, CH-1011 Lausanne, Switzerland.
Véronique ValletInstitute of Radiation Physics, Lausanne University Hospital and University of Lausanne, CH-1011 Lausanne, Switzerland.ORCID 0000-0002-1876-4805
Vincent DunetLundin Family Brain Tumor Centre, Departments of Oncology & Clinical Neurosciences, Hospital and University of Lausanne, CH-1011 Lausanne, Switzerland.ORCID 0000-0002-9897-4561
Hasna BouchaabDepartments of Medical Oncology, Lausanne University Hospital and University of Lausanne, CH-1011 Lausanne, Switzerland.
Solange PetersDepartments of Medical Oncology, Lausanne University Hospital and University of Lausanne, CH-1011 Lausanne, Switzerland.
Constantin TuleascaLundin Family Brain Tumor Centre, Departments of Oncology & Clinical Neurosciences, Hospital and University of Lausanne, CH-1011 Lausanne, Switzerland.
Jean BourhisDepartment of Radiation Oncology, Lausanne University Hospital and University of Lausanne, CHUV, Rue du Bugnon 46, CH-1011 Lausanne, Switzerland.
Luis SchiappacasseDepartment of Radiation Oncology, Lausanne University Hospital and University of Lausanne, CHUV, Rue du Bugnon 46, CH-1011 Lausanne, Switzerland.ORCID 0000-0001-7621-1662

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeto evaluate an SRT approach in patients with at least 10 lesions at the time of BM initial diagnosis.

methodsThis is a monocentric prospective cohort of patients treated by SRT, followed by a brain MRI every two months. Subsequent SRT could be delivered in cases of new BMs during follow-up. The main endpoints were local control rate (LCR), overall survival (OS), and strategy success rate (SSR). Acute and late toxicity were evaluated.

resultsSeventy patients were included from October 2014 to January 2019, and the most frequent primary diagnosis was non-small-cell lung cancer (N = 36, 51.4%). A total of 1174 BMs were treated at first treatment, corresponding to a median number of 14 BMs per patient. Most of the patients (N = 51, 72.6%) received a single fraction of 20-24 Gy. At 1 year, OS was 62.3%, with a median OS of 19.2 months, and SSR was 77.8%. A cumulative number of 1537 BM were treated over time, corresponding to a median cumulative number of 16 BM per patient. At 1-year, the LCR was 97.3%, with a cumulative incidence of radio-necrosis of 2.1% per lesion. Three patients (4.3%) presented Grade 2 toxicity, and there was no Grade ≥ 3 toxicity. The number of treated BMs and the treatment volume did not influence OS or SSR (

conclusionsSRT was highly efficient in controlling the BM, with minimal side effects. In this setting, an SRT treatment should be proposed even in patients with ≥10 BMs at diagnosis.

Indexed as

brain metastasesSRSstereotactic radiotherapy

Identifiers

PMID38730695
PMCPMC11083879

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.